Fig. 2From: What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND studyChange in HbA1c 1 year after a limited response to a new medication stratified by treatment decision after response HbA1c: continue, switch, or add. a Adjusted HbA1c change in the complete cohort (n = 12,168). Response adjusted for age, gender, duration of diabetes, HbA1c at initiation of the first new therapy, year of treatment, and line of therapy (second or third). b Unadjusted HbA1c in propensity score-matched groups (n = 3351). Matched on age, gender, duration of diabetes, HbA1c at initiation of the first new therapy, and 6-month HbA1c response to the first new therapyBack to article page